Moon Surgical
Moon Surgical (previously MastOR SAS) is a Paris-based, early-stage medical device company, developing a surgical robot for laparoscopy assistance. It is a privately held portfolio company of Sofinnova Partners, financed through the MD Start III Fund. The core technology is derived from joint research between the ISIR robotics lab at Sorbonne University and Professor Brice Gayet, a world-renowned surgeon and pioneer in minimally-invasive surgery.
Sector
Medical Devices
Strategies
MD Start & Capital
Status
Live
Website
www.moonsurgical.com
Anne Osdoit
Partner, Sofinnova Partners - MD Start Strategy
Antoine Papiernik
Chairman & Managing Partner, Sofinnova Partners
Related News
Moon Surgical Expands Leadership Team to Accelerate Commercial Growth Across U.S. and Europe
Moon Surgical receives FDA clearance for ScoPilot™ on Maestro, industry's first AI-enhanced intraoperative capability, powered by NVIDIA Holoscan
Global debut in an ASC setting at Surgeon's Point Surgery Center for Moon Surgical's Maestro System
Moon Surgical appoints Chris Toth as Independent Board Member ahead of commercial acceleration
Enhanced data security and quality via ISO 27001:2022 and SOC 2 certifications enables Moon Surgical to deliver actionable insights to healthcare providers
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.